Mereo BioPharma Group PLC
MREO0.670USD
-0.046-6.43%
Close 01/15, 16:00（ET）Quotes delayed by 15 min
533.37MMarket Cap
LossP/E TTM
More Details of Mereo BioPharma Group PLC Company
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Mereo BioPharma Group PLC Info
Ticker SymbolMREO
Company nameMereo BioPharma Group PLC
IPO dateJun 09, 2016
CEOScots-Knight (Denise V)
Number of employees36
Security typeDepository Receipt
Fiscal year-endJun 09
AddressOne Cavendish Place
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW1G0QF
Phone443330237300
Websitehttps://www.mereobiopharma.com/
Ticker SymbolMREO
IPO dateJun 09, 2016
CEOScots-Knight (Denise V)
Company Executives of Mereo BioPharma Group PLC
Name
Name/Position
Position
Shareholding
Change
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+60223.00%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+29851.00%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
+12550.00%
Dr. Denise Scots-Knight, Ph.D.
Dr. Denise Scots-Knight, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Charles E. Sermon
Mr. Charles E. Sermon
General Counsel and Business Development, Company Secretary
General Counsel and Business Development, Company Secretary
--
--
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Christine Fox
Ms. Christine Fox
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pierre Jacquet, M.D., Ph.D.
Dr. Pierre Jacquet, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Alexandra (Wills) Hughes-Wilson
Ms. Alexandra (Wills) Hughes-Wilson
Chief Patient Access and Commercial Planning
Chief Patient Access and Commercial Planning
94.77K
+60223.00%
Dr. John A. Lewicki, Ph.D.
Dr. John A. Lewicki, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
78.63K
+29851.00%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.05K
--
Dr. Jeremy Bender, Ph.D.
Dr. Jeremy Bender, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
12.55K
+12550.00%
Dr. Denise Scots-Knight, Ph.D.
Dr. Denise Scots-Knight, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Anders Ekblom, M.D., Ph.D.
Dr. Anders Ekblom, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.24%
Rubric Capital Management LP
9.62%
683 Capital Management LLC
8.18%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Other
59.18%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
10.24%
Rubric Capital Management LP
9.62%
683 Capital Management LLC
8.18%
Northpond Ventures, LLC
6.85%
Frazier Life Sciences Management, L.P.
5.93%
Other
59.18%
Shareholder Types
Shareholders
Proportion
Hedge Fund
28.27%
Investment Advisor/Hedge Fund
18.45%
Venture Capital
7.29%
Investment Advisor
6.24%
Private Equity
5.93%
Research Firm
3.42%
Individual Investor
0.86%
Bank and Trust
0.40%
Pension Fund
0.02%
Other
29.10%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
171
119.57M
75.14%
+8.80M
2025Q3
170
111.71M
70.22%
-5.91M
2025Q2
167
124.56M
78.34%
-3.58M
2025Q1
176
112.84M
70.99%
-23.15M
2024Q4
174
116.69M
75.21%
-16.90M
2024Q3
167
107.29M
69.42%
-17.56M
2024Q2
164
101.82M
66.22%
-5.20M
2024Q1
162
84.96M
60.56%
-41.79M
2023Q4
143
78.69M
56.11%
-37.03M
2023Q3
141
72.18M
51.57%
-33.53M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
16.29M
10.24%
-1.40M
-7.91%
Sep 30, 2025
Rubric Capital Management LP
15.31M
9.62%
--
--
Sep 30, 2025
683 Capital Management LLC
13.02M
8.18%
+8.14M
+167.01%
Dec 29, 2025
Northpond Ventures, LLC
10.90M
6.85%
+10.90M
--
Jun 04, 2025
Frazier Life Sciences Management, L.P.
9.44M
5.93%
--
--
Sep 30, 2025
Mangrove Partners
7.79M
4.9%
-845.90K
-9.79%
Sep 30, 2025
abrdn Inc.
5.54M
3.48%
+2.51M
+82.86%
Sep 30, 2025
Rock Springs Capital Management LP
4.57M
2.87%
+105.36K
+2.36%
Sep 30, 2025
Clearline Capital LP
3.83M
2.41%
+216.00K
+5.97%
Sep 30, 2025
Alkeon Capital Management LLC
3.70M
2.32%
-1.00M
-21.29%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
0.58%
Virtus LifeSci Biotech Clinical Trials ETF
0.46%
SPDR S&P International Small Cap ETF
0.03%
ActivePassive International Equity ETF
0.01%
Tema Heart & Health ETF
0%
Tema Oncology ETF
0%
Formidable ETF
0%
iShares Genomics Immunology and Healthcare ETF
Proportion0.58%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.46%
SPDR S&P International Small Cap ETF
Proportion0.03%
ActivePassive International Equity ETF
Proportion0.01%
Tema Heart & Health ETF
Proportion0%
Tema Oncology ETF
Proportion0%
Formidable ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Mereo BioPharma Group PLC?
The top five shareholders of Mereo BioPharma Group PLC are:
Janus Henderson Investors holds 16.29M shares, accounting for 10.24% of the total shares.
Rubric Capital Management LP holds 15.31M shares, accounting for 9.62% of the total shares.
683 Capital Management LLC holds 13.02M shares, accounting for 8.18% of the total shares.
Northpond Ventures, LLC holds 10.90M shares, accounting for 6.85% of the total shares.
Frazier Life Sciences Management, L.P. holds 9.44M shares, accounting for 5.93% of the total shares.
Janus Henderson Investors holds 16.29M shares, accounting for 10.24% of the total shares.
Rubric Capital Management LP holds 15.31M shares, accounting for 9.62% of the total shares.
683 Capital Management LLC holds 13.02M shares, accounting for 8.18% of the total shares.
Northpond Ventures, LLC holds 10.90M shares, accounting for 6.85% of the total shares.
Frazier Life Sciences Management, L.P. holds 9.44M shares, accounting for 5.93% of the total shares.
What are the top three shareholder types of Mereo BioPharma Group PLC?
The top three shareholder types of Mereo BioPharma Group PLC are:
Janus Henderson Investors
Rubric Capital Management LP
683 Capital Management LLC
Janus Henderson Investors
Rubric Capital Management LP
683 Capital Management LLC
How many institutions hold shares of Mereo BioPharma Group PLC (MREO)?
As of 2025Q4, 171 institutions hold shares of Mereo BioPharma Group PLC, with a combined market value of approximately 119.57M, accounting for 75.14% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 4.92%.
What is the biggest source of revenue for Mereo BioPharma Group PLC?
In --, the -- business generated the highest revenue for Mereo BioPharma Group PLC, amounting to -- and accounting for --% of total revenue.
